About the Project |  FAQs |  Glossary |  Data Sources |  Bibliography |  Complete Indicator List

Indicator Details: Crude Prevalence of CKD Stages 1–4a
Data Sources
 
Stratification and Year Choices:
View Data By:

  Source
  • NHANES

  Chart Format
  Chart Colors
Select a state from the dropdown below

State: 
County: 
Data: 





Filter By:

Sort By:




Footnotes:
a Stages 1 and 2 defined by single assessment of albuminuria (i.e., no estimation of persistence) and eGFR ≥90 and 60-89 ml/min/1.73 m², respectively; stages 3 and 4 defined as 30-59 and 15-29 ml/min/1.73 m², respectively.




Crude prevalence of CKD stages 1-4 remained stable over the time periods 2001 to 2020, with a prevalence of approximately 14.7% in 2017 to March 2020. Prevalence was estimated to be highest in people aged 70 years or older, females, non-Hispanic blacks, persons with diabetes, and persons with hypertension.

Chart Explanation: 

From 2001 to 2020, the overall crude prevalence of CKD ranged between 13.3% and 14.7%. Over this time, the crude prevalence was consistently highest in older individuals. In 2017-March 2020, 42.6% of people aged 70 years or older were classified as having CKD, compared to 6.0% in those aged 18 to 39 years. In the same years, prevalence continued to be higher in females (15.9%) than in males (13.4%). Non-Hispanic blacks had the highest prevalence estimate for most years (14.4% to 16.7%), while Mexican Americans (11.2% to 12.9%) consistently had the lowest prevalence. Compared to their counterparts, in 2017-March 2020, people with diabetes (38.5%) or hypertension (26.3%) had a higher prevalence of CKD than people without these conditions (10.8% and 7.7% respectively). As expected, this has remained the same from 2001 to 2020.
The National Health and Nutrition Examination Survey (NHANES) is a nationally representative, cross-sectional survey that is currently conducted every 2 years by the Centers for Disease Control and Prevention's National Center for Health Statistics to examine disease prevalence and trends over time in noninstitutionalized U.S. civilian residents.

The survey consists of a standardized in-home interview and a physical examination with blood and urine collected at a mobile examination center (MEC). Here, we examined data from 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014, 2015-2016, 2017-March 2020 NHANES. The estimated glomerular filtration rate (eGFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation for calibrated creatinine (Levey et al., 2009). Serum creatinine was calibrated for 1999-2000 and 2005-2006 participants; no correction was required for calibrated serum creatinine in participants in the 2001-2002, 2003-2004, 2007-2008, 2009-2010, 2011-2012, 2013-2014, and 2015-2016 surveys (Selvin et al., 2007). Albuminuria was defined by urinary albumin-to-creatinine ratio ≥30 mg/g; moderate albuminuria ranges between 30 and 299 mg/g and severe albuminuria is ≥300 mg/g; pregnant women were excluded. For comparisons across the 18-year period 1999-2016, albuminuria was corrected in 1999-2006 to account for differences in the instrumentation and method for urine creatinine starting in 2007. The prevalence of CKD is likely overestimated by single measurements of albuminuria and kidney function (eGFR). In clinical practice, CKD is defined by persistent albuminuria or reduced kidney function for ≥3 months.

FieldData
Description of MeasurePrevalence of CKD stage 1-4
Data SourceNCHS
Type of Data SourcePublic
Data SetNHANES
Health Care System DataNo
Regional or National?National
Demographic Group

Noninstitutionalized U.S. residents aged 18+ years

NumeratorParticipants with CKD
DenominatorParticipants with serum creatinine and urine protein measurements
Definition of CKDStage 1, eGFR ≥ 90 ml/min/1.73 m² and presence of single albuminuria; Stage 2, eGFR 60-89 ml/min/1.73 m² and presence of single albuminuria; Stage 3, eGFR 30-59 ml/min/1.73 m²; Stage 4, 15-29 ml/min/1.73 m²; Stage 5, excluded
Glomerular filtration rateEstimated using CKD-EPI equation for calibrated creatinine: eGFR=141 x [min(calibrated serum creatinine in mg/dL) /κ, 1)]α x [max(calibrated serum creatinine in mg/dL/κ, 1)]κ  x 0.993age x (1.018 if female) x (1.159 if NH Black)
κ = 0.7 if female, and 0.9 if male
α = -0.329 if female, and -0.411 if male
ProteinuriaUrinary albumin-to-creatinine ratios of 30-299 mg/g (microalbuminuria) and >300 mg/g (macroalbuminuria); pregnant/menstruating women excluded
Primary Data Source Indicatorlbxscr: Serum creatinine
Primary Indicator Method of MeasurementExamination/Laboratory
Secondary (1) Variableridageyr: Age in years
Secondary (1) Indicator Method of MeasurementQuestionnaire (interviewer-administered)
Secondary (2) Variableridgendr: Gender
Secondary (2) Indicator Method of MeasurementQuestionnaire (interviewer-administered)
Secondary (3) VariableNo
Secondary (3) Indicator Method of Measurementridreth1: Race/ethnicity
Secondary (3) from Medical Record? Questionnaire (interviewer-administered)
Secondary (4) Data Source Indicatorurxuma: Urine albumin
Secondary (4) Indicator Method of Measurement Examination/lab
Secondary (5) Data Source Indicatorurxucr: Urine creatinine
Secondary (5) Indicator Method of Measurement Examination/lab
Frequency of Measurement (Primary)Once (cross-sectional)
U.S. Region Covered by Primary VariableAll
Period Currently Available1999–2016
Pending Data2017-2018
Additional Data Items of InterestStage of CKD, year, other stratification variables of interest (diabetes by self-report, hypertension by self-report)
Limitations of IndicatorAlbuminuria and kidney function can only be assessed from a one-time cross-sectional measurement, leading to overestimation of prevalence; second measures of albuminuria are available for only 2009-2010 and were first-morning rather than spot urine samples; no second measures of creatinine
Analytic ConsiderationsAppropriate NHANES survey weights must be used for all analyses; creatinine measurements must be calibrated for NHANES III, 1999-2000 and 2005-2006; many variable names differ across surveys; if SE 30% or more of estimate, must report as “low precision”
References and Sources:
  • Levey AS, Stevens LA, Schmid CH, et al. A New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 2009;150(9):604-612.

    http://annals.org/aim/article/744469
  • Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis. 2003;41(1):1-12.
    http://www.ncbi.nlm.nih.gov/pubmed/12500213
  • Selvin E, Manzi J, Stevens LA, et al. Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988-1994, 1999-2004. Am J Kidney Dis. 2007;50(6):918-26.

Suggested Citation:
Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States.
website. http://www.cdc.gov/ckd